159 related articles for article (PubMed ID: 8395068)
1. Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma.
Raeburn D; Souness JE; Tomkinson A; Karlsson JA
Prog Drug Res; 1993; 40():9-32. PubMed ID: 8395068
[No Abstract] [Full Text] [Related]
2. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Nicholson CD; Challiss RA; Shahid M
Trends Pharmacol Sci; 1991 Jan; 12(1):19-27. PubMed ID: 1848733
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Murray KJ; England PJ
Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
[No Abstract] [Full Text] [Related]
4. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma.
Giembycz MA; Dent G
Clin Exp Allergy; 1992 Mar; 22(3):337-44. PubMed ID: 1316796
[No Abstract] [Full Text] [Related]
5. Cyclic nucleotide phosphodiesterase isoenzymes and asthma--outstanding issues.
Nicholson CD
Agents Actions Suppl; 1993; 43():3-12. PubMed ID: 8396317
[TBL] [Abstract][Full Text] [Related]
6. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.
Thompson WJ
Pharmacol Ther; 1991; 51(1):13-33. PubMed ID: 1663250
[TBL] [Abstract][Full Text] [Related]
7. Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources.
Noguera MA; Ivorra MD; Lugnier C; D'Ocon P
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jun; 363(6):612-9. PubMed ID: 11414656
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
Torphy TJ; Livi GP; Balcarek JM; White JR; Chilton FH; Undem BJ
Adv Second Messenger Phosphoprotein Res; 1992; 25():289-305. PubMed ID: 1372813
[No Abstract] [Full Text] [Related]
9. [Progress in the study of cyclic nucleotide phosphodiesterases].
Zhou HL; Bian RL
Sheng Li Ke Xue Jin Zhan; 1995 Jul; 26(3):213-7. PubMed ID: 8584886
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Nicholson CD; Shahid M; Bruin J; Barron E; Spiers I; de Boer J; van Amsterdam RG; Zaagsma J; Kelly JJ; Dent G
J Pharmacol Exp Ther; 1995 Aug; 274(2):678-87. PubMed ID: 7636728
[TBL] [Abstract][Full Text] [Related]
11. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.
Beavo JA; Reifsnyder DH
Trends Pharmacol Sci; 1990 Apr; 11(4):150-5. PubMed ID: 2159198
[TBL] [Abstract][Full Text] [Related]
12. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo.
Raeburn D; Karlsson JA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1147-52. PubMed ID: 8263775
[TBL] [Abstract][Full Text] [Related]
13. [Molecular cardiopharmacology of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes].
Tanaka T; Mukai J; Naka M
Nihon Yakurigaku Zasshi; 1992 Sep; 100(3):249-58. PubMed ID: 1328001
[TBL] [Abstract][Full Text] [Related]
14. 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition.
Drees M; Zimmermann R; Eisenbrand G
Cancer Res; 1993 Jul; 53(13):3058-61. PubMed ID: 8391385
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide phosphodiesterases in the circulatory system. Biochemical, pharmacological, and functional characteristics.
Weishaar RE; Kobylarz-Singer D; Keiser JA; Wright CD; Cornicelli J; Panek R
Adv Second Messenger Phosphoprotein Res; 1992; 25():249-69. PubMed ID: 1313261
[No Abstract] [Full Text] [Related]
16. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.
Hall IP
Br J Clin Pharmacol; 1993 Jan; 35(1):1-7. PubMed ID: 8383516
[No Abstract] [Full Text] [Related]
17. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts.
Keravis T; Thaseldar-Roumié R; Lugnier C
Methods Mol Biol; 2005; 307():63-74. PubMed ID: 15988055
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells.
Tani T; Sakurai K; Kimura Y; Ishikawa T; Hidaka H
Adv Second Messenger Phosphoprotein Res; 1992; 25():215-27. PubMed ID: 1372812
[No Abstract] [Full Text] [Related]
19. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
